BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23241075)

  • 1. Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers.
    Secreto G; Venturelli E; Meneghini E; Carcangiu ML; Paolini B; Agresti R; Pellitteri C; Berrino F; Gion M; Cogliati P; Saragò G; Micheli A
    BMC Cancer; 2012 Dec; 12():599. PubMed ID: 23241075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-Menopausal Women With Breast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes.
    Rajarajan S; Korlimarla A; Alexander A; Anupama CE; Ramesh R; Srinath BS; Sridhar TS; Prabhu JS
    Front Endocrinol (Lausanne); 2021; 12():679756. PubMed ID: 34234742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
    Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
    Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor expression and breast cancer survival in postmenopausal women.
    Hu R; Dawood S; Holmes MD; Collins LC; Schnitt SJ; Cole K; Marotti JD; Hankinson SE; Colditz GA; Tamimi RM
    Clin Cancer Res; 2011 Apr; 17(7):1867-74. PubMed ID: 21325075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women.
    Fourkala EO; Zaikin A; Burnell M; Gentry-Maharaj A; Ford J; Gunu R; Soromani C; Hasenbrink G; Jacobs I; Dawnay A; Widschwendter M; Lichtenberg-Fraté H; Menon U
    Endocr Relat Cancer; 2012 Apr; 19(2):137-47. PubMed ID: 22199143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer.
    Wellberg EA; Checkley LA; Giles ED; Johnson SJ; Oljira R; Wahdan-Alaswad R; Foright RM; Dooley G; Edgerton SM; Jindal S; Johnson GC; Richer JK; Kabos P; Thor AD; Schedin P; MacLean PS; Anderson SM
    Horm Cancer; 2017 Dec; 8(5-6):269-285. PubMed ID: 28741260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adult body size and physical activity in relation to risk of breast cancer according to tumor androgen receptor status.
    Zhang X; Eliassen AH; Tamimi RM; Hazra A; Beck AH; Brown M; Collins LC; Rosner B; Hankinson SE
    Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):962-8. PubMed ID: 25855627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential impact of the expression of the androgen receptor by age in estrogen receptor-positive breast cancer.
    Tokunaga E; Hisamatsu Y; Taketani K; Yamashita N; Akiyoshi S; Okada S; Tanaka K; Saeki H; Oki E; Aishima S; Oda Y; Morita M; Maehara Y
    Cancer Med; 2013 Dec; 2(6):763-73. PubMed ID: 24403250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of androgen receptors in primary breast cancer.
    Park S; Koo J; Park HS; Kim JH; Choi SY; Lee JH; Park BW; Lee KS
    Ann Oncol; 2010 Mar; 21(3):488-492. PubMed ID: 19887463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased androgen receptor expression in estrogen receptor-positive/progesterone receptor-negative breast cancer.
    García X; Elía A; Galizzi L; May M; Spengler E; Martínez Vázquez P; Burruchaga J; Gass H; Lanari C; Lamb CA
    Breast Cancer Res Treat; 2020 Feb; 180(1):257-263. PubMed ID: 31950383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study.
    Kahán Z; Gardi J; Nyári T; Földesi I; Hajnal-Papp R; Ormándi K; Lázár G; Thurzó L; Schally AV
    Int J Oncol; 2006 Jul; 29(1):193-200. PubMed ID: 16773200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers.
    Ogawa Y; Hai E; Matsumoto K; Ikeda K; Tokunaga S; Nagahara H; Sakurai K; Inoue T; Nishiguchi Y
    Int J Clin Oncol; 2008 Oct; 13(5):431-5. PubMed ID: 18946753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
    Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
    J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone and biological characteristics of breast cancers in postmenopausal women.
    Secreto G; Venturelli E; Meneghini E; Greco M; Ferraris C; Gion M; Zancan M; Fabricio AS; Berrino F; Cavalleri A; Micheli A
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):2942-8. PubMed ID: 19843675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Li W; O'Shaughnessy J; Hayes D; Campone M; Bondarenko I; Zbarskaya I; Brain E; Stenina M; Ivanova O; Graas MP; Neven P; Ricci D; Griffin T; Kheoh T; Yu M; Gormley M; Martin J; Schaffer M; Zelinsky K; De Porre P; Johnston SR
    Clin Cancer Res; 2016 Dec; 22(24):6002-6009. PubMed ID: 27267854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer?
    Arslan C; Isik M; Guler G; Kulac I; Solak M; Turker B; Ozisik Y; Altundag K
    Am Surg; 2012 Sep; 78(9):992-9. PubMed ID: 22964210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen, estrogen, and progesterone receptor levels in malignant and benign breast tumors: a multivariate analysis approach.
    Brentani MM; Franco EL; Oshima CT; Pacheco MM
    Int J Cancer; 1986 Nov; 38(5):637-42. PubMed ID: 3770993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating sex hormones and tumor characteristics in postmenopausal breast cancer patients. A cross-sectional study.
    Secreto G; Meneghini E; Venturelli E; Cogliati P; Agresti R; Ferraris C; Gion M; Zancan M; Fabricio AS; Berrino F; Cavalleri A; Micheli A
    Int J Biol Markers; 2011; 26(4):241-6. PubMed ID: 22180173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate.
    Buchanan G; Birrell SN; Peters AA; Bianco-Miotto T; Ramsay K; Cops EJ; Yang M; Harris JM; Simila HA; Moore NL; Bentel JM; Ricciardelli C; Horsfall DJ; Butler LM; Tilley WD
    Cancer Res; 2005 Sep; 65(18):8487-96. PubMed ID: 16166329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Masculinizing hormone therapy effect on breast tissue: Changes in estrogen and androgen receptors in transgender female-to-male mastectomies.
    Chaum M; Grossi S; Chen J; Hu V; Ray E; Giuliano A; Bose S
    Breast; 2023 Dec; 72():103596. PubMed ID: 37951051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.